Sciadonics, Inc.

Arctic Nutrition As

Metabolon, Inc.

The Cleveland Clinic Foundation

Meabolon, Inc.

Artic Nutrition As

University of Michigan

Alvin Berger

Arul M Chinnaiyan

Jan Remmereit

Hogne Hallaraker

Kay A Lawton

Matthew W Mitchell

Arun Sreekumar

Bruce J McCreedy

Christopher William Beecher

Christopher Beecher

Satish C Kalhan

Imran A Shah

YunFu Hu

Chris Beecher

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-&#x3b2;-oxidizable fatty acid analogues such as tetradecylthioacetic acid.

Lipid compositions containing bioactive fatty acids

The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.

Lipid compositions with high DHA content

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5,9,12-octadecatrienoic acid; 7,11,14-eicosatrienoic acid; 5,8,11,14-eicosatetraenoic acid; 9,12-octadecadienoic acid; 9-octadecenoic acid; 14-methyl hexadecanoic acid; 11,14 eicosadienoic acid, 5,9-octadecadienoic acid; 5,11-octadecadienoic acid; 9,12,15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid.

Lipid formulations containing bioactive fatty acids

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of juniperonic acid alone or in combination with other bioactive fatty acids and lipids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, sciadonic acid, conjugated linoleic acid, non-&#x3b2;-oxidizable fatty acid analogues such as tetradecylthioacetic acid, fish oil, olive oil, and pine nut oil.

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-&#x3b2;-oxidizable fatty acid analoges such as tetradecylthioacetic acid.

The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

Biomarkers for fatty liver disease and methods using the same

Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer.

Biomarkers for prostate cancer and methods using the same

Methods for the measurement and prediction of response to hepatotoxicants and carcinogens through the detection of metabolites in a mammal are provided. The metabolites can be used as biomarkers, including efficacy biomarkers, surrogate biomarkers, and toxicity biomarkers. The methods find use for early prediction of toxicity, target identification/validation, and monitoring of drug efficacy.

Growing community of inventors

Long Lake, MN, United States of America

Alvin Berger